Randomized Controlled Trial
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2025; 17(1): 99272
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.99272
Effects of Shenqi Xiangyi granules in advanced gastric cancer chemotherapy
Xiao-Jing Shi, Yu Song, Xue-Xue Liang, Ting Chen, Huang-Yu Hao, Xue Han, Ya-Nan Chen
Xiao-Jing Shi, Yu Song, Xue-Xue Liang, Ting Chen, Huang-Yu Hao, Xue Han, Ya-Nan Chen, Department of Oncology, Zhangjiagang First People's Hospital, Suzhou 215600, Jiangsu Province, China
Co-first authors: Xiao-Jing Shi and Yu Song.
Author contributions: Shi XJ and Song Y contributed equally to this work; Shi XJ and Song Y designed the study; Shi XJ, Song Y, Liang XX, Chen T, Hao HY, Han X and Chen YN contributed to the analysis of the manuscript; Shi XJ, Song Y, Liang XX, Chen T, Hao HY, Han X and Chen YN involved in the data and writing of this article; Shi XJ and Song Y are jointly responsible for data collection, design research, and have made equal contributions to this article (so designated Shi XJ and Song Y as co first authors); All authors have read and approved the final manuscript.
Institutional review board statement: This study was reviewed and approved by the Institutional Review Board of Zhangjiagang First People's Hospital, No. 2021-Z-1254.
Clinical trial registration statement: The study was registered at the Clinical Trial Center (www.researchregistry.com) with registration number: researchregistry10707.
Informed consent statement: All study participants and their legal guardians provided written informed consent before recruitment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data is available.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ya-Nan Chen, MMed, Doctor, Department of Oncology, Zhangjiagang First People's Hospital, No. 68 Jiyang West Road, Zhangjiagang, Suzhou 215600, Jiangsu Province, China. chenyanan@126.com
Received: August 28, 2024
Revised: September 21, 2024
Accepted: October 18, 2024
Published online: January 15, 2025
Processing time: 106 Days and 1.3 Hours
Core Tip

Core Tip: Reasonable and effective treatment with traditional Chinese medicine is crucial for patients with advanced cancer, especially those receiving chemotherapy and targeted therapy.